Jan Steyaert

Jan Steyaert is the founder of Confo Therapeutics, a VIB-VUB spin-off developing GPCR-targeted drugs using conformational antibody technology.

2 News mentions

Overview

Jan Steyaert is a professor at Vrije Universiteit Brussel and director of the Structural Biology Brussels lab at Vrije Universiteit Brussel, as well as Deputy-Director of the Structural Biology Research Center of Flanders Institute for Biotechnology. He founded Confo Therapeutics in 2015 as a spin-off from his lab at Vrije Universiteit Brussel and Flanders Institute for Biotechnology, based on the ConfoBody technology he developed for stabilizing GPCRs in pharmacologically relevant conformations. He is also a co-founder of Ablynx and Biotalys, and won the Jacob and Louise Gabbay Award in Biotechnology and Medicine in 2022.

Career history

  1. FounderConfo Therapeutics

In the news

This page shows public professional information only, each fact cited. Is this you? send a correction, or ask for removal within 24 hours, no questions asked.